<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/mostaccessed/journal?journal=bmcmedgenet&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Medical Genetics - Most accessed articles</title>
        <link>http://www.biomedcentral.com/bmcmedgenet/</link>
        <description>The most accessed research articles published by BMC Medical Genetics</description>
        <dc:date>2009-11-12T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/7/84" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/10/102" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/10/111" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/10/113" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/10/6" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/10/115" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/10/98" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/10/114" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/10/110" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/10/104" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/7/84">
        <title>A novel mutation in the SH3BP2 gene causes cherubism: case report</title>
        <description>Background:
Cherubism is a rare hereditary multi-cystic disease of the jaws, characterized by its typical appearance in early childhood, and stabilization and remission after puberty. It is genetically transmitted in an autosomal dominant fashion and the gene coding for SH3-binding protein 2 (SH3BP2) may be involved.Case presentationWe investigated a family consisting of 21 members with 3 female affected individuals with cherubism from Northern China. Of these 21 family members, 17 were recruited for the genetic analysis. We conducted the direct sequence analysis of the SH3BP2 gene among these 17 family members. A disease-causing mutation was identified in exon 9 of the gene. It was an A1517G base change, which leads to a D419G amino acid substitution.
Conclusion:
To our knowledge, the A1517G mutation has not been reported previously in cherubism. This finding is novel.</description>
        <link>http://www.biomedcentral.com/1471-2350/7/84</link>
                <dc:creator>Cui-Ying Li</dc:creator>
                <dc:creator>Shi-Feng Yu</dc:creator>
                <dc:source>BMC Medical Genetics 2006, 7:84</dc:source>
        <dc:date>2006-12-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-7-84</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>84</prism:startingPage>
        <prism:publicationDate>2006-12-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/10/102">
        <title>Autism genetic database (AGD): a comprehensive database including autism susceptibility gene-CNVs integrated with known noncoding RNAs and fragile sites</title>
        <description>Background:
Autism is a highly heritable complex neurodevelopmental disorder, therefore identifying its genetic basis has been challenging. To date, numerous susceptibility genes and chromosomal abnormalities have been reported in association with autism, but most discoveries either fail to be replicated or account for a small effect. Thus, in most cases the underlying causative genetic mechanisms are not fully understood. In the present work, the Autism Genetic Database (AGD) was developed as a literature-driven, web-based, and easy to access database designed with the aim of creating a comprehensive repository for all the currently reported genes and genomic copy number variations (CNVs) associated with autism in order to further facilitate the assessment of these autism susceptibility genetic factors.DescriptionAGD is a relational database that organizes data resulting from exhaustive literature searches for reported susceptibility genes and CNVs associated with autism. Furthermore, genomic information about human fragile sites and noncoding RNAs was also downloaded and parsed from miRBase, snoRNA-LBME-db, piRNABank, and the MIT/ICBP siRNA database. A web client genome browser enables viewing of the features while a web client query tool provides access to more specific information for the features. When applicable, links to external databases including GenBank, PubMed, miRBase, snoRNA-LBME-db, piRNABank, and the MIT siRNA database are provided.
Conclusion:
AGD comprises a comprehensive list of susceptibility genes and copy number variations reported to-date in association with autism, as well as all known human noncoding RNA genes and fragile sites. Such a unique and inclusive autism genetic database will facilitate the evaluation of autism susceptibility factors in relation to known human noncoding RNAs and fragile sites, impacting on human diseases. As a result, this new autism database offers a valuable tool for the research community to evaluate genetic findings for this complex multifactorial disorder in an integrated format. AGD provides a genome browser and a web based query client for conveniently selecting features of interest. Access to AGD is freely available at http://wren.bcf.ku.edu/.</description>
        <link>http://www.biomedcentral.com/1471-2350/10/102</link>
                <dc:creator>Gregory Matuszek</dc:creator>
                <dc:creator>Zohreh Talebizadeh</dc:creator>
                <dc:source>BMC Medical Genetics 2009, 10:102</dc:source>
        <dc:date>2009-09-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-10-102</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>102</prism:startingPage>
        <prism:publicationDate>2009-09-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/10/111">
        <title>Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis</title>
        <description>Background:
Plasma level of high-density lipoprotein-cholesterol (HDL-C), a heritable trait, is an important determinant of susceptibility to atherosclerosis. Non-synonymous and regulatory single nucleotide polymorphisms (SNPs) in genes implicated in HDL-C synthesis and metabolism are likely to influence plasma HDL-C, apolipoprotein A-I (apo A-I) levels and severity of coronary atherosclerosis.
Methods:
We genotyped 784 unrelated Caucasian individuals from two sets of populations (Lipoprotein and Coronary Atherosclerosis Study- LCAS, N = 333 and TexGen, N = 451) for 94 SNPs in 42 candidate genes by 5&apos; nuclease assays. We tested the distribution of the phenotypes by the Shapiro-Wilk normality test. We used Box-Cox regression to analyze associations of the non-normally distributed phenotypes (plasma HDL-C and apo A-I levels) with the genotypes. We included sex, age, body mass index (BMI), diabetes mellitus (DM), and cigarette smoking as covariates. We calculated the q values as indicators of the false positive discovery rate (FDR).
Results:
Plasma HDL-C levels were associated with sex (higher in females), BMI (inversely), smoking (lower in smokers), DM (lower in those with DM) and SNPs in APOA5, APOC2, CETP, LPL and LIPC (each q &#8804;0.01). Likewise, plasma apo A-I levels, available in the LCAS subset, were associated with SNPs in CETP, APOA5, and APOC2 as well as with BMI, sex and age (all q values &#8804;0.03). The APOA5 variant S19W was also associated with minimal lumen diameter (MLD) of coronary atherosclerotic lesions, a quantitative index of severity of coronary atherosclerosis (q = 0.018); mean number of coronary artery occlusions (p = 0.034) at the baseline and progression of coronary atherosclerosis, as indicated by the loss of MLD.
Conclusion:
Putatively functional variants of APOA2, APOA5, APOC2, CETP, LPL, LIPC and SOAT2 are independent genetic determinants of plasma HDL-C levels. The non-synonymous S19W SNP in APOA5 is also an independent determinant of plasma apo A-I level, severity of coronary atherosclerosis and its progression.</description>
        <link>http://www.biomedcentral.com/1471-2350/10/111</link>
                <dc:creator>Suet Nee Chen</dc:creator>
                <dc:creator>Mehmet Cilingiroglu</dc:creator>
                <dc:creator>Joshua Todd</dc:creator>
                <dc:creator>Raffaella Lombardi</dc:creator>
                <dc:creator>James Willerson</dc:creator>
                <dc:creator>Antonio Gotto</dc:creator>
                <dc:creator>Christie Ballantne</dc:creator>
                <dc:creator>A Marian</dc:creator>
                <dc:source>BMC Medical Genetics 2009, 10:111</dc:source>
        <dc:date>2009-10-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-10-111</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>111</prism:startingPage>
        <prism:publicationDate>2009-10-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/10/113">
        <title>ALDH1A2 (RALDH2) genetic variation in human congenital heart disease </title>
        <description>Background:
Signaling by the vitamin A-derived morphogen retinoic acid (RA) is required at multiple steps of cardiac development. Since conversion of retinaldehyde to RA by retinaldehyde dehydrogenase type II (ALDH1A2, a.k.a RALDH2) is critical for cardiac development, we screened patients with congenital heart disease (CHDs) for genetic variation at the ALDH1A2 locus.
Methods:
One-hundred and thirty-three CHD patients were screened for genetic variation at the ALDH1A2 locus through bi-directional sequencing. In addition, six SNPs (rs2704188, rs1441815, rs3784259, rs1530293, rs1899430) at the same locus were studied using a TDT-based association approach in 101 CHD trios. Observed mutations were modeled through molecular mechanics (MM) simulations using the AMBER 9 package, Sander and Pmemd programs. Sequence conservation of observed mutations was evaluated through phylogenetic tree construction from ungapped alignments containing ALDH8 s, ALDH1Ls, ALDH1 s and ALDH2 s. Trees were generated by the Neighbor Joining method. Variations potentially affecting splicing mechanisms were cloned and functional assays were designed to test splicing alterations using the pSPL3 splicing assay.
Results:
We describe in Tetralogy of Fallot (TOF) the mutations Ala151Ser and Ile157Thr that change non-polar to polar residues at exon 4. Exon 4 encodes part of the highly-conserved tetramerization domain, a structural motif required for ALDH oligomerization. Molecular mechanics simulation studies of the two mutations indicate that they hinder tetramerization. We determined that the SNP rs16939660, previously associated with spina bifida and observed in patients with TOF, does not affect splicing. Moreover, association studies performed with classical models and with the transmission disequilibrium test (TDT) design using single marker genotype, or haplotype information do not show differences between cases and controls.
Conclusion:
In summary, our screen indicates that ALDH1A2 genetic variation is present in TOF patients, suggesting a possible causal role for this gene in rare cases of human CHD, but does not support the hypothesis that variation at the ALDH1A2 locus is a significant modifier of the risk for CHD in humans.</description>
        <link>http://www.biomedcentral.com/1471-2350/10/113</link>
                <dc:creator>Marilene Pavan</dc:creator>
                <dc:creator>Vivane Ruiz</dc:creator>
                <dc:creator>Fabio Silva</dc:creator>
                <dc:creator>Tiago Sobreira</dc:creator>
                <dc:creator>Roberta Cravo</dc:creator>
                <dc:creator>Michelle Vasconcelos</dc:creator>
                <dc:creator>Livia Marques</dc:creator>
                <dc:creator>Sonia Mesquita</dc:creator>
                <dc:creator>Jose Krieger</dc:creator>
                <dc:creator>Antonio Lopes</dc:creator>
                <dc:creator>Paulo Oliveira</dc:creator>
                <dc:creator>Alexandre Pereira</dc:creator>
                <dc:creator>Jose Xavier-Neto</dc:creator>
                <dc:source>BMC Medical Genetics 2009, 10:113</dc:source>
        <dc:date>2009-11-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-10-113</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>113</prism:startingPage>
        <prism:publicationDate>2009-11-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/10/6">
        <title>An Open Access Database of Genome-wide Association Results</title>
        <description>Background:
The number of genome-wide association studies (GWAS) is growing rapidly leading to the discovery and replication of many new disease loci. Combining results from multiple GWAS datasets may potentially strengthen previous conclusions and suggest new disease loci, pathways or pleiotropic genes. However, no database or centralized resource currently exists that contains anywhere near the full scope of GWAS results.
Methods:
We collected available results from 118 GWAS articles into a database of 56,411 significant SNP-phenotype associations and accompanying information, making this database freely available here. In doing so, we met and describe here a number of challenges to creating an open access database of GWAS results. Through preliminary analyses and characterization of available GWAS, we demonstrate the potential to gain new insights by querying a database across GWAS.
Results:
Using a genomic bin-based density analysis to search for highly associated regions of the genome, positive control loci (e.g., MHC loci) were detected with high sensitivity. Likewise, an analysis of highly repeated SNPs across GWAS identified replicated loci (e.g., APOE, LPL). At the same time we identified novel, highly suggestive loci for a variety of traits that did not meet genome-wide significant thresholds in prior analyses, in some cases with strong support from the primary medical genetics literature (SLC16A7, CSMD1, OAS1), suggesting these genes merit further study. Additional adjustment for linkage disequilibrium within most regions with a high density of GWAS associations did not materially alter our findings. Having a centralized database with standardized gene annotation also allowed us to examine the representation of functional gene categories (gene ontologies) containing one or more associations among top GWAS results. Genes relating to cell adhesion functions were highly over-represented among significant associations (p &lt; 4.6 &#215; 10-14), a finding which was not perturbed by a sensitivity analysis.
Conclusion:
We provide access to a full gene-annotated GWAS database which could be used for further querying, analyses or integration with other genomic information. We make a number of general observations. Of reported associated SNPs, 40% lie within the boundaries of a RefSeq gene and 68% are within 60 kb of one, indicating a bias toward gene-centricity in the findings. We found considerable heterogeneity in information available from GWAS suggesting the wider community could benefit from standardization and centralization of results reporting.</description>
        <link>http://www.biomedcentral.com/1471-2350/10/6</link>
                <dc:creator>Andrew Johnson</dc:creator>
                <dc:creator>Christopher O'Donnell</dc:creator>
                <dc:source>BMC Medical Genetics 2009, 10:6</dc:source>
        <dc:date>2009-01-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-10-6</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2009-01-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/10/115">
        <title>PIN1 gene variants in Alzheimer&apos;s disease</title>
        <description>Background:
Peptidyl-prolyl isomerase, NIMA-interacting 1 (PIN1) plays a significant role in the brain and is implicated in numerous cellular processes related to Alzheimer&apos;s disease (AD) and other neurodegenerative conditions. There are confounding results concerning PIN1 activity in AD brains. Also PIN1 genetic variation was inconsistently associated with AD risk.
Methods:
We performed analysis of coding and promoter regions of PIN1 in early- and late-onset AD and frontotemporal dementia (FTD) patients in comparison with healthy controls.
Results:
Analysis of eighteen PIN1 common polymorphisms and their haplotypes in EOAD, LOAD and FTD individuals in comparison with the control group did not reveal their contribution to disease risk.In six unrelated familial AD patients four novel PIN1 sequence variants were detected. c.58+64C&gt;T substitution that was identified in three patients, was located in an alternative exon. In silico analysis suggested that this variant highly increases a potential affinity for a splicing factor and introduces two intronic splicing enhancers. In the peripheral leukocytes of one living patient carrying the variant, a 2.82 fold decrease in PIN1 expression was observed.
Conclusion:
Our data does not support the role of PIN1 common polymorphisms as AD risk factor. However, we suggest that the identified rare sequence variants could be directly connected with AD pathology, influencing PIN1 splicing and/or expression.</description>
        <link>http://www.biomedcentral.com/1471-2350/10/115</link>
                <dc:creator>Aleksandra Maruszak</dc:creator>
                <dc:creator>Krzysztof Safranow</dc:creator>
                <dc:creator>Katarzyna Gustaw</dc:creator>
                <dc:creator>Beata Kijanowska-Haladyna</dc:creator>
                <dc:creator>Katarzyna Jakubowska</dc:creator>
                <dc:creator>Maria Olszewska</dc:creator>
                <dc:creator>Maria Styczynska</dc:creator>
                <dc:creator>Mariusz Berdynski</dc:creator>
                <dc:creator>Andrzej Tysarowski</dc:creator>
                <dc:creator>Dariusz Chlubek</dc:creator>
                <dc:creator>Janusz Siedlecki</dc:creator>
                <dc:creator>Maria Barcikowska</dc:creator>
                <dc:creator>Cezary Zekanowski</dc:creator>
                <dc:source>BMC Medical Genetics 2009, 10:115</dc:source>
        <dc:date>2009-11-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-10-115</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>115</prism:startingPage>
        <prism:publicationDate>2009-11-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/10/98">
        <title>Genomewide Association Study for Onset Age in Parkinson Disease</title>
        <description>Background:
Age at onset in Parkinson disease (PD) is a highly heritable quantitative trait for which a significant genetic influence is supported by multiple segregation analyses. Because genes associated with onset age may represent invaluable therapeutic targets to delay the disease, we sought to identify such genetic modifiers using a genomewide association study in familial PD. There have been previous genomewide association studies (GWAS) to identify genes influencing PD susceptibility, but this is the first to identify genes contributing to the variation in onset age.
Methods:
Initial analyses were performed using genotypes generated with the Illumina HumanCNV370Duo array in a sample of 857 unrelated, familial PD cases. Subsequently, a meta-analysis of imputed SNPs was performed combining the familial PD data with that from a previous GWAS of 440 idiopathic PD cases. The SNPs from the meta-analysis with the lowest p-values and consistency in the direction of effect for onset age were then genotyped in a replication sample of 747 idiopathic PD cases from the Parkinson Institute Biobank of Milan, Italy.
Results:
Meta-analysis across the three studies detected consistent association (p &lt; 1 &#215; 10-5) with five SNPs, none of which reached genomewide significance. On chromosome 11, the SNP with the lowest p-value (rs10767971; p = 5.4 &#215; 10-7) lies between the genes QSER1 and PRRG4. Near the PARK3 linkage region on chromosome 2p13, association was observed with a SNP (rs7577851; p = 8.7 &#215; 10-6) which lies in an intron of the AAK1 gene. This gene is closely related to GAK, identified as a possible PD susceptibility gene in the GWAS of the familial PD cases.
Conclusion:
Taken together, these results suggest an influence of genes involved in endocytosis and lysosomal sorting in PD pathogenesis.</description>
        <link>http://www.biomedcentral.com/1471-2350/10/98</link>
                <dc:creator>Jeanne Latourelle</dc:creator>
                <dc:creator>Nathan Pankratz</dc:creator>
                <dc:creator>Alexandra Dumitriu</dc:creator>
                <dc:creator>Jemma Wilk</dc:creator>
                <dc:creator>Stefano Goldwurm</dc:creator>
                <dc:creator>Gianni Pezzoli</dc:creator>
                <dc:creator>Claudio Mariani</dc:creator>
                <dc:creator>Anita Destefano</dc:creator>
                <dc:creator>Cheryl Halter</dc:creator>
                <dc:creator>James Gusella</dc:creator>
                <dc:creator>William Nichols</dc:creator>
                <dc:creator>Richard Myers</dc:creator>
                <dc:creator>Tatiana Foroud</dc:creator>
                <dc:creator>PSG -PROGENI Investigators and Coordinators</dc:creator>
                <dc:creator>PSG -PROGENI Molecular Genetic Laboratory</dc:creator>
                <dc:creator>GenePD Investigators and Coordinators</dc:creator>
                <dc:creator>GenePD Molecular Genetics Laboratories</dc:creator>
                <dc:source>BMC Medical Genetics 2009, 10:98</dc:source>
        <dc:date>2009-09-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-10-98</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>98</prism:startingPage>
        <prism:publicationDate>2009-09-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/10/114">
        <title>Voltage-dependent anion channel (VDAC) is involved in apoptosis of cell lines carrying the mitochondrial DNA mutation </title>
        <description>Background:
The mitochondrial voltage-dependent anion channel (VDAC) is increasingly implicated in the control of apoptosis. We have studied the effects the mitochondrial DNA (mtDNA) tRNAIle mutation on VDAC expression, localization, and apoptosis.
Methods:
Lymphoblastoid cell lines were derived from 3 symptomatic and 1 asymptomatic members of a family with hypertension associated with the A4263G tRNAIle mutation as well as from control subjects. Mitochondrial potential (&#916;&#936;m) and apoptosis were measured by flow cytometry; co-localization of VDAC and Bax was evaluated by confocal microscopy.
Results:
Expression of VDAC and Bax in mtDNA cell lines was found to be increased compared to controls, while expression of the small conductance calcium-dependant potassium channel (sKCa) was unchanged. Confocal imaging revealed co-localization of VDAC/Bax on the outer mitochondrial membrane of A4263G cell lines but not from controls. Flow cytometry indicated that the mitochondrial potential was decreased by 32% in mutated cells versus controls while rates of apoptosis were increased (P &lt; 0.05). The difference was attenuated by Cyclosporin A (CsA, 2 &#956;M), a blocker of VDAC.
Conclusion:
We conclude that increased expression of mitochondrial VDAC and subcellular co-localization of VDAC/Bax increases mitochondrial permeability and apoptosis in cell lines carrying the mtDNA tRNAIle A4263G mutation.</description>
        <link>http://www.biomedcentral.com/1471-2350/10/114</link>
                <dc:creator>Liu Yuqi</dc:creator>
                <dc:creator>Li Yang</dc:creator>
                <dc:creator>Li Zongbin</dc:creator>
                <dc:creator>Xu Hua</dc:creator>
                <dc:creator>Wen Yi</dc:creator>
                <dc:creator>Wang Lin</dc:creator>
                <dc:creator>Guan Minxin</dc:creator>
                <dc:creator>Gao Lei</dc:creator>
                <dc:creator>Wang Shiwen</dc:creator>
                <dc:source>BMC Medical Genetics 2009, 10:114</dc:source>
        <dc:date>2009-11-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-10-114</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>114</prism:startingPage>
        <prism:publicationDate>2009-11-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/10/110">
        <title>Telomere shortening may be associated with human keloids</title>
        <description>Background:
Keloids are benign skin tumors that are the effect of a dysregulated wound-healing process in genetically predisposed patients. They are inherited with an autosomal dominant mode with incomplete clinical penetrance and variable expression. Keloids are characterized by formation of excess scar tissue beyond the boundaries of the wound. The exact etiology is still unknown and there is currently no appropriate treatment for keloid disease.
Methods:
We analyzed sample tissues were obtained from 20 patients with keloid skin lesions and normal skin was obtained from 20 healthy donors. The telomeres were measured by Terminal Restriction Fragment (TRF) analysis and Real-Time PCR assay. Quantitative Real-Time RT-PCR analysis of hTERT gene expression was performed and intracellular ROS generation was measured.
Results:
In this study, we determined whether telomeric shortening and the expression of human telomerase reverse transcriptase (hTERT) occurs in keloid patients. Using Terminal Restriction Fragment (TRF) analysis and Real-Time PCR assay, we detected a significant telomere shortening of 30% in keloid specimens compared to normal skin. Using quantitative Real-Time RT-PCR, telomerase activity was found absent in the keloid tissues. Moreover, an increase in ROS generation was detected in fibroblasts cell cultures from keloid specimens as more time elapsed compared to fibroblasts from normal skin.
Conclusion:
Telomere shortening has been reported in several metabolic and cardiovascular diseases. We found that telomere shortening can also be associated with human keloids. Chronic oxidative stress plays a major role in the pathophysiology of several chronic inflammatory diseases. Here we found increased ROS generation in fibroblasts from keloid fibroblasts cell cultures when compared to normal skin fibroblasts. Hence we conclude that oxidative stress might be an important modulator of telomere loss in keloid because of the absence of active telomerase that counteracts telomere shortening.</description>
        <link>http://www.biomedcentral.com/1471-2350/10/110</link>
                <dc:creator>Bruna De Felice</dc:creator>
                <dc:creator>Robert Wilson</dc:creator>
                <dc:creator>Massimo Nacca</dc:creator>
                <dc:source>BMC Medical Genetics 2009, 10:110</dc:source>
        <dc:date>2009-10-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-10-110</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>110</prism:startingPage>
        <prism:publicationDate>2009-10-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/10/104">
        <title>The role of CACNA1S in predisposition to malignant hyperthermia</title>
        <description>Background:
Malignant hyperthermia (MH) is an inherited pharmacogenetic disorder of skeletal muscle, characterised by an elevated calcium release from the skeletal muscle sarcoplasmic reticulum. The dihydropyridine receptor (DHPR) plays an essential role in excitation-contraction coupling and calcium homeostasis in skeletal muscle. This study focuses on the gene CACNA1S which encodes the &#945;1 subunit of the DHPR, in order to establish whether CACNA1S plays a major role in MH susceptibility in the UK.
Methods:
We investigate the CACNA1S locus in detail in 50 independent MH patients, the largest study to date, to identify novel variants that may predispose to disease and also to characterise the haplotype structure across CACNA1S.
Results:
We present CACNA1S cDNA sequencing data from 50 MH patients in whom RYR1 mutations have been excluded, and subsequent mutation screening analysis. Furthermore we present haplotype analysis of unphased CACNA1S SNPs to (1) assess CACNA1S haplotype frequency differences between susceptible MH cases and a European control group and (2) analyse population-based association via clustering of CACNA1S haplotypes based on disease risk.
Conclusion:
The study identified a single potentially pathogenic change in CACNA1S (p.Arg174Trp), and highlights that the haplotype structure across CACNA1S is diverse, with a high degree of variability.</description>
        <link>http://www.biomedcentral.com/1471-2350/10/104</link>
                <dc:creator>Danielle Carpenter</dc:creator>
                <dc:creator>Christopher Ringrose</dc:creator>
                <dc:creator>Vincenzo Leo</dc:creator>
                <dc:creator>Andrew Morris</dc:creator>
                <dc:creator>Rachel Robinson</dc:creator>
                <dc:creator>P Jane Halsall</dc:creator>
                <dc:creator>Philip Hopkins</dc:creator>
                <dc:creator>Marie-Anne Shaw</dc:creator>
                <dc:source>BMC Medical Genetics 2009, 10:104</dc:source>
        <dc:date>2009-10-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-10-104</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>104</prism:startingPage>
        <prism:publicationDate>2009-10-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
